{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T20:19:11Z","timestamp":1649189951809},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.medcli.2012.12.011","type":"journal-article","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T00:02:59Z","timestamp":1361577779000},"page":"111-113","source":"Crossref","is-referenced-by-count":0,"title":["Leucemia mieloide cr\u00f3nica y resistencia al tratamiento con inhibidores de la tirosincinasa: mutaciones en ABL, \u00bfmucho ruido y pocas nueces?"],"prefix":"10.1016","volume":"141","author":[{"given":"Mar\u00eda Teresa","family":"G\u00f3mez Casares","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia G.","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2012.12.011_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.medcli.2012.12.011_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.medcli.2012.12.011_bib0015","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.12.011_bib0020","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.medcli.2012.12.011_bib0025","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.12.011_bib0030","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2012.12.011_bib0035","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medcli.2012.12.011_bib0040","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of BCR-ABL inhibitors AMN107 and BMS-54825 against clinically relevant imatinib-resistant ABL kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.medcli.2012.12.011_bib0045","article-title":"MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1)","author":"G\u00f3mez-Casares","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.medcli.2012.12.011_bib0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.medcli.2012.10.028","article-title":"Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors","volume":"141","author":"Marc\u00e9","year":"2013","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2012.12.011_bib0055","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.12.011_bib0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cancergen.2012.09.003","article-title":"The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with Imatinib mesylate","volume":"205","author":"Lee","year":"2012","journal-title":"Cancer Genet"},{"key":"10.1016\/j.medcli.2012.12.011_bib0065","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2012.12.011_bib0070","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/pgs.12.103","article-title":"Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: The evolving role of Bcr-Abl mutations and mutational analysis","volume":"13","author":"Soverini","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.medcli.2012.12.011_bib0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2012.12.011_bib0080","doi-asserted-by":"crossref","first-page":"1208-1215","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.12.011_bib0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2012.09.012","article-title":"Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure","volume":"37","author":"Shih","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2012.12.011_bib0090","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2012.12.011_bib0095","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2012.12.011_bib0100","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.medcli.2012.12.011_bib0105","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.12.011_bib0110","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T01:47:53Z","timestamp":1562723273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0025775313000079"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2012.12.011","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}